America's biotech leadership is being challenged — and experts say U.S. policy isn't keeping up. At a recent Axios roundtable in Washington, regulators, investors, and patient advocates sounded the alarm on China's rapid biopharma advances, calling them the result of a deliberate strategy by the Chinese Communist Party to dominate global biotechnology. The stakes, they argued, span national security, patient care, and drug discovery.

The conversation surfaced a clear consensus: the U.S. needs a coordinated, government-wide biopharma strategy. Panelists flagged regulatory barriers as a key competitive disadvantage, with one investor warning that without reform, China will "continue to eat our lunch." FDA leadership was also spotlighted, with the agency's deputy commissioner expressing confidence in Trump's FDA pick, Heidi Overton, to drive policy efficiently.

Key Takeaways:

• China's biotech rise is intentional — driven by a national CCP strategy, not just market forces
• U.S. regulatory hurdles are hampering competitiveness against Chinese drugmakers
• A "whole-of-government" approach is needed, but coordination at the White House level is currently lacking
• Workforce development must keep pace alongside drug innovation and national security investments

Why it matters: The global biotech race isn't just about profits — it's about who controls the future of medicine. Without policy reform and strategic coordination, the U.S. risks ceding ground in a sector critical to both public health and national security.